Yahoo · Nov 5, 2026
Repligen: 3 Key Takeaways for Long-Term Investors
Services revenue is building a recurring base while capital orders suggest stronger sales ahead.
NASDAQ · RGEN
Healthcare · Medical - Instruments & Supplies
$172.67
Down-$2.38 (-1.38%)
Updated Nov 20, 2026, 1:16 AM
SID Score
5.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance · RGEN
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 18, 2026
RGEN closed at $172.67 after 20 trading sessions, down 3.38% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 18, 2026 | $163.03 | $174.435 | $163.01 | $172.67 | 1.3M |
| Nov 17, 2026 | $162.78 | $165.34 | $160.27 | $162.18 | 770.86K |
| Nov 16, 2026 | $166.14 | $166.79 | $162.48 | $162.78 | 575.43K |
| Nov 13, 2026 | $168.09 | $169.04 | $165.26 | $167.79 | 510.11K |
| Nov 12, 2026 | $167.71 | $169.40 | $163.85 | $166.52 | 802.98K |
| Nov 11, 2026 | $176.11 | $178.50 | $171.99 | $172.62 | 1M |
| Nov 10, 2026 | $176.76 | $178.375 | $173.85 | $173.98 | 678.65K |
| Nov 9, 2026 | $174.29 | $181.015 | $172.39 | $178.94 | 1.1M |
| Nov 6, 2026 | $169.35 | $175.00 | $168.05 | $173.49 | 1.07M |
| Nov 5, 2026 | $175.60 | $176.655 | $168.03 | $168.48 | 1.33M |
| Nov 4, 2026 | $183.40 | $188.50 | $174.39 | $178.20 | 1.06M |
| Nov 3, 2026 | $175.54 | $181.56 | $173.00 | $178.27 | 1.02M |
| Nov 2, 2026 | $178.12 | $178.12 | $172.505 | $172.95 | 1.58M |
| Oct 30, 2026 | $177.44 | $180.45 | $171.23 | $176.94 | 4.47M |
| Oct 29, 2026 | $188.42 | $191.05 | $185.275 | $188.64 | 890.27K |
| Oct 28, 2026 | $173.54 | $185.88 | $173.54 | $184.69 | 1.45M |
| Oct 27, 2026 | $168.34 | $180.00 | $164.88 | $175.80 | 2.11M |
| Oct 26, 2026 | $176.93 | $181.46 | $175.80 | $180.17 | 1.18M |
| Oct 23, 2026 | $178.30 | $179.54 | $174.90 | $176.93 | 1.07M |
| Oct 22, 2026 | $179.45 | $185.025 | $175.96 | $178.71 | 1.27M |
The latest Smart Investors Daily articles mentioning RGEN.
Company
Market Activity
Research & News
RGEN research
Company profile and research snapshot.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 28, 2026 | RBC Capital | Outperform | — |
| Oct 19, 2026 | Canaccord Genuity | Hold | — |
| Oct 7, 2026 | Barclays | Overweight | — |
| Sep 9, 2026 | UBS | Buy | — |
| Jul 30, 2026 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
Yahoo · Nov 5, 2026
Services revenue is building a recurring base while capital orders suggest stronger sales ahead.
Yahoo · Nov 4, 2026
WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that it will participate in the Jefferies Global Healthcare Conference in London, UK. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst-led discussion on November 18th at 2:00 p.m. GMT. A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website and will be available for replay for a limited period of time f
SeekingAlpha · Nov 3, 2026
Baron SMID Cap ETF returned -2.87% (NAV) in the third quarter, outperforming its benchmark, the Russell 2500 Growth Index, which returned -10.35%. Read more here.
Yahoo · Nov 1, 2026
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 10.9% year on year to $209.3 million. The company’s full-year revenue guidance of $848 million at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $0.53 per share was 14.5% above analysts’ consensus estimates.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning RGEN.